TAK · Takeda Pharmaceutical Co ADR
United States · RS rating 95 · As of 2026-11-03
| Price | 20.75 USD |
|---|---|
| 1-day change | -0.6% |
| RS rating (overall / 1M / 3M / 12M) | 95 / 91 / 91 / 86 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 50 / 70 / 42 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +7.1% |
| Distance from 52-week high | +0.8% |
| Market cap (USD) | $52.6B |